Scholarlink

Background <p>Despite the widespread clinical use of allopurinol for managing hepatocellular carcinoma (HCC) and gout, its potential hepatotoxicity and its effect on the risk of HCC remain unclear. This study aimed to comprehensively assess the potential correlations between allopurinol exposure and HCC risk.</p> Methods <p>We utilized genome-wide association study data from the IEU OpenGWAS project as instrumental variables (IVs) for Mendelian randomization (MR) analysis to investigate the causal relationship between allopurinol and HCC. Subsequently, we investigated the potential mediating factors (gout, liver fat, and percentage of liver fat, etc.) between allopurinol use and HCC. Furthermore, we analyzed assessed survival outcomes using the Kaplan–Meier method to compare patient subgroups by differential Xanthine dehydrogenase (XDH) expression.</p> Results <p>MR analysis established a causal link between allopurinol use and increased HCC risk (OR: 1.013, 95% CI 1.004–1.023, p = 0.006). Causal relationships were also observed between gout (OR: 1.011, p = 0.008) and HCC. Mediation analysis indicated that gout mediated 61.6% of the effect of allopurinol on HCC. Survival analysis showed that higher expression of XDH was associated with improved survival of HCC patients (HR = 0.62, 95% CI 0.441–0.884, p = 0.008), indicating a 38% decrease in mortality risk compared to the lower expression group.</p> Conclusions <p>This study demonstrated a causal relationship between allopurinol&#xa0;use and an&#xa0;increased risk of HCC based on genetic evidence. Allopurinol should be used with caution in patients with or at risk for HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between allopurinol and hepatocellular carcinoma: analysis of genetic risk and patient survival

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月2日

查看全文
  • Yu-fu Li,
  • Hui-wei Wang,
  • Huan-yan Peng,
  • Zhen-ying Zhang,
  • Zhi-jia Yao,
  • Yuan Meng,
  • Dong-ye Yang

摘要

Background

Despite the widespread clinical use of allopurinol for managing hepatocellular carcinoma (HCC) and gout, its potential hepatotoxicity and its effect on the risk of HCC remain unclear. This study aimed to comprehensively assess the potential correlations between allopurinol exposure and HCC risk.

Methods

We utilized genome-wide association study data from the IEU OpenGWAS project as instrumental variables (IVs) for Mendelian randomization (MR) analysis to investigate the causal relationship between allopurinol and HCC. Subsequently, we investigated the potential mediating factors (gout, liver fat, and percentage of liver fat, etc.) between allopurinol use and HCC. Furthermore, we analyzed assessed survival outcomes using the Kaplan–Meier method to compare patient subgroups by differential Xanthine dehydrogenase (XDH) expression.

Results

MR analysis established a causal link between allopurinol use and increased HCC risk (OR: 1.013, 95% CI 1.004–1.023, p = 0.006). Causal relationships were also observed between gout (OR: 1.011, p = 0.008) and HCC. Mediation analysis indicated that gout mediated 61.6% of the effect of allopurinol on HCC. Survival analysis showed that higher expression of XDH was associated with improved survival of HCC patients (HR = 0.62, 95% CI 0.441–0.884, p = 0.008), indicating a 38% decrease in mortality risk compared to the lower expression group.

Conclusions

This study demonstrated a causal relationship between allopurinol use and an increased risk of HCC based on genetic evidence. Allopurinol should be used with caution in patients with or at risk for HCC.